Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density

Detalhes bibliográficos
Autor(a) principal: Nunes,Frederico Arthur Pereira
Data de Publicação: 2021
Outros Autores: Farias,Maria Lucia Fleiuss de, Oliveira,Felipe Peres, Vieira Neto,Leonardo, Lima,Luis Felipe Cardoso, Paranhos Neto,Francisco de Paula, Mendonça,Laura Maria Carvalho de, Madeira,Miguel
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos de Endocrinologia e Metabolismo (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972021000400505
Resumo: ABSTRACT Objective: To evaluate changes in bone density and architecture in postmenopausal women with breast cancer (BC) and use of aromatase inhibitor (AI). Subjects and methods: Thirty-four postmenopausal women with BC, without bone metastasis, renal function impairment and who were not receiving bone-active drugs were selected from a population of 523 outpatients treated for BC. According to the presence of hormonal receptors, HER2 and Ki67, seventeen had positive hormonal receptors and received anastrozole (AI group), and seventeen were triple-negative receptors (non-AI group), previously treated with chemotherapy. Areal bone mineral density (aBMD) and vertebral fracture assessment (VFA) analyses were performed by DXA; vBMD and bone microarchitecture were evaluated by HR-pQCT. Fracture risk was estimated using the FRAX tool. Results: No patient referred previous low-impact fracture, and VFA detected one moderate vertebral fracture in a non-AI patient. AI patients showed lower aBMD and BMD T-scores at the hip and 33% radius and a higher proportion of osteoporosis diagnosis on DXA (47%) vs non-AI (17.6%). AI group had significantly lower values for vBMD at the entire, cortical and trabecular bone compartments, cortical and trabecular thickness and BV/TV. They also had a higher risk for major fractures and for hip fractures estimated by FRAX. Several HR-pQCT parameters evaluated at distal radius and distal tibia were significantly associated with fracture risk. Conclusion: AI is associated with alterations in bone density and microarchitecture of both the cortical and trabecular compartments. These findings explain the overall increase in fracture risk in this specific population.
id SBEM-1_ba53c4d7b201243bd81ce1f9ab6177a4
oai_identifier_str oai:scielo:S2359-39972021000400505
network_acronym_str SBEM-1
network_name_str Arquivos de Endocrinologia e Metabolismo (Online)
repository_id_str
spelling Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and densityBreast cancerosteoporosisaromatase inhibitors (AI)bone mineral density (BMD)high resolution peripheral quantitative computed tomography (HR-pQCT)ABSTRACT Objective: To evaluate changes in bone density and architecture in postmenopausal women with breast cancer (BC) and use of aromatase inhibitor (AI). Subjects and methods: Thirty-four postmenopausal women with BC, without bone metastasis, renal function impairment and who were not receiving bone-active drugs were selected from a population of 523 outpatients treated for BC. According to the presence of hormonal receptors, HER2 and Ki67, seventeen had positive hormonal receptors and received anastrozole (AI group), and seventeen were triple-negative receptors (non-AI group), previously treated with chemotherapy. Areal bone mineral density (aBMD) and vertebral fracture assessment (VFA) analyses were performed by DXA; vBMD and bone microarchitecture were evaluated by HR-pQCT. Fracture risk was estimated using the FRAX tool. Results: No patient referred previous low-impact fracture, and VFA detected one moderate vertebral fracture in a non-AI patient. AI patients showed lower aBMD and BMD T-scores at the hip and 33% radius and a higher proportion of osteoporosis diagnosis on DXA (47%) vs non-AI (17.6%). AI group had significantly lower values for vBMD at the entire, cortical and trabecular bone compartments, cortical and trabecular thickness and BV/TV. They also had a higher risk for major fractures and for hip fractures estimated by FRAX. Several HR-pQCT parameters evaluated at distal radius and distal tibia were significantly associated with fracture risk. Conclusion: AI is associated with alterations in bone density and microarchitecture of both the cortical and trabecular compartments. These findings explain the overall increase in fracture risk in this specific population.Sociedade Brasileira de Endocrinologia e Metabologia2021-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972021000400505Archives of Endocrinology and Metabolism v.65 n.4 2021reponame:Arquivos de Endocrinologia e Metabolismo (Online)instname:Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)instacron:SBEM10.20945/2359-3997000000385info:eu-repo/semantics/openAccessNunes,Frederico Arthur PereiraFarias,Maria Lucia Fleiuss deOliveira,Felipe PeresVieira Neto,LeonardoLima,Luis Felipe CardosoParanhos Neto,Francisco de PaulaMendonça,Laura Maria Carvalho deMadeira,Migueleng2021-09-16T00:00:00Zoai:scielo:S2359-39972021000400505Revistahttps://www.aem-sbem.com/https://old.scielo.br/oai/scielo-oai.php||aem.editorial.office@endocrino.org.br2359-42922359-3997opendoar:2021-09-16T00:00Arquivos de Endocrinologia e Metabolismo (Online) - Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)false
dc.title.none.fl_str_mv Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density
title Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density
spellingShingle Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density
Nunes,Frederico Arthur Pereira
Breast cancer
osteoporosis
aromatase inhibitors (AI)
bone mineral density (BMD)
high resolution peripheral quantitative computed tomography (HR-pQCT)
title_short Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density
title_full Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density
title_fullStr Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density
title_full_unstemmed Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density
title_sort Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density
author Nunes,Frederico Arthur Pereira
author_facet Nunes,Frederico Arthur Pereira
Farias,Maria Lucia Fleiuss de
Oliveira,Felipe Peres
Vieira Neto,Leonardo
Lima,Luis Felipe Cardoso
Paranhos Neto,Francisco de Paula
Mendonça,Laura Maria Carvalho de
Madeira,Miguel
author_role author
author2 Farias,Maria Lucia Fleiuss de
Oliveira,Felipe Peres
Vieira Neto,Leonardo
Lima,Luis Felipe Cardoso
Paranhos Neto,Francisco de Paula
Mendonça,Laura Maria Carvalho de
Madeira,Miguel
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Nunes,Frederico Arthur Pereira
Farias,Maria Lucia Fleiuss de
Oliveira,Felipe Peres
Vieira Neto,Leonardo
Lima,Luis Felipe Cardoso
Paranhos Neto,Francisco de Paula
Mendonça,Laura Maria Carvalho de
Madeira,Miguel
dc.subject.por.fl_str_mv Breast cancer
osteoporosis
aromatase inhibitors (AI)
bone mineral density (BMD)
high resolution peripheral quantitative computed tomography (HR-pQCT)
topic Breast cancer
osteoporosis
aromatase inhibitors (AI)
bone mineral density (BMD)
high resolution peripheral quantitative computed tomography (HR-pQCT)
description ABSTRACT Objective: To evaluate changes in bone density and architecture in postmenopausal women with breast cancer (BC) and use of aromatase inhibitor (AI). Subjects and methods: Thirty-four postmenopausal women with BC, without bone metastasis, renal function impairment and who were not receiving bone-active drugs were selected from a population of 523 outpatients treated for BC. According to the presence of hormonal receptors, HER2 and Ki67, seventeen had positive hormonal receptors and received anastrozole (AI group), and seventeen were triple-negative receptors (non-AI group), previously treated with chemotherapy. Areal bone mineral density (aBMD) and vertebral fracture assessment (VFA) analyses were performed by DXA; vBMD and bone microarchitecture were evaluated by HR-pQCT. Fracture risk was estimated using the FRAX tool. Results: No patient referred previous low-impact fracture, and VFA detected one moderate vertebral fracture in a non-AI patient. AI patients showed lower aBMD and BMD T-scores at the hip and 33% radius and a higher proportion of osteoporosis diagnosis on DXA (47%) vs non-AI (17.6%). AI group had significantly lower values for vBMD at the entire, cortical and trabecular bone compartments, cortical and trabecular thickness and BV/TV. They also had a higher risk for major fractures and for hip fractures estimated by FRAX. Several HR-pQCT parameters evaluated at distal radius and distal tibia were significantly associated with fracture risk. Conclusion: AI is associated with alterations in bone density and microarchitecture of both the cortical and trabecular compartments. These findings explain the overall increase in fracture risk in this specific population.
publishDate 2021
dc.date.none.fl_str_mv 2021-08-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972021000400505
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972021000400505
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.20945/2359-3997000000385
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Endocrinologia e Metabologia
publisher.none.fl_str_mv Sociedade Brasileira de Endocrinologia e Metabologia
dc.source.none.fl_str_mv Archives of Endocrinology and Metabolism v.65 n.4 2021
reponame:Arquivos de Endocrinologia e Metabolismo (Online)
instname:Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)
instacron:SBEM
instname_str Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)
instacron_str SBEM
institution SBEM
reponame_str Arquivos de Endocrinologia e Metabolismo (Online)
collection Arquivos de Endocrinologia e Metabolismo (Online)
repository.name.fl_str_mv Arquivos de Endocrinologia e Metabolismo (Online) - Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)
repository.mail.fl_str_mv ||aem.editorial.office@endocrino.org.br
_version_ 1752122518069575680